Suppr超能文献

肿瘤取栓患者围手术期结局与生存标志物相关吗?

Are markers of survival associated with perioperative outcomes for tumor thrombectomy patients?

机构信息

Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.

University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.

出版信息

Urol Oncol. 2023 Aug;41(8):358.e17-358.e24. doi: 10.1016/j.urolonc.2023.05.015. Epub 2023 Jun 8.

Abstract

INTRODUCTION

Despite modern advances in surgical and perioperative technologies, management of renal cell carcinoma (RCC) with tumor thrombus (TT) is a morbid procedure that necessitates careful patient selection. It is not known whether established prognostic models for metastatic RCC are suitable prognostic tools for more immediate perioperative outcomes in patients with RCC with TT. We evaluated if established risk models for cytoreductive nephrectomy, as a potential extension of their purpose-built use, are associated with immediate perioperative outcomes in patients undergoing nephrectomy and tumor thrombectomy.

METHODS

Perioperative outcomes of patients who underwent radical nephrectomy and tumor thrombectomy for RCC were compared to presences of established predictors of long-term outcomes from prior risk models individually and as stratified by risk grouping (International Metastatic Renal-Cell Carcinoma Database Consortium [IMDC], Memorial Sloan Kettering Cancer Center [MSKCC], M.D. Anderson Cancer Center [MDACC], and Moffitt Cancer Center [MCC]). Wilcoxon rank-sum test or the Kruskal-Wallis test compared continuous variables and the chi-square test or Fisher's exact test compared categorical variables.

RESULTS

Fifty-five patients were analyzed with 17 (30.9%) being cytoreductive. Eighteen (32.7%) patients had a level III or higher TT. Individually, preoperative variables were inconsistently associated with perioperative outcomes. Poorer risk patients per the IMDC model had more major postoperative complications (Clavien-Dindo grade≥3, P = 0.008). For the MSKCC model, poorer risk patients had increased intraoperative estimated blood loss (EBL), longer length of stay (LOS), more major postoperative complications, and more likely to discharge to a rehabilitation facility (P < 0.05). Less favorable risk patients per MDACC model had increased LOS (P = 0.038). Poorer risk patients per the MCC model had increased EBL, LOS, major postoperative complications, and 30-day hospital readmissions (P < 0.05).

CONCLUSION

Overall, cytoreductive risks models were heterogeneously associated with perioperative outcomes in patients undergoing nephrectomy and tumor thrombectomy. Of available models, the MCC model is associated with more perioperative outcomes including EBL, LOS, major postoperative complications, and readmissions within 30 days when compared to the IMDC, MSKCC, and MDACC models.

摘要

简介

尽管现代外科和围手术期技术取得了进步,但肾细胞癌(RCC)伴肿瘤栓子(TT)的治疗仍然是一种复杂的手术,需要仔细选择患者。目前尚不清楚转移性 RCC 的既定预后模型是否适合 RCC 伴 TT 患者更直接的围手术期结局的预后工具。我们评估了作为其特定用途扩展的肾细胞减瘤切除术的既定风险模型,是否与接受肾切除术和肿瘤栓切除术的患者的即刻围手术期结局相关。

方法

比较接受根治性肾切除术和肿瘤栓切除术治疗 RCC 的患者的围手术期结局与既往风险模型中既定的长期结局预测因子的存在情况,这些预测因子分别作为个体存在,并且根据风险分组(国际转移性肾细胞癌数据库联盟[IMDC]、纪念斯隆凯特琳癌症中心[MSKCC]、安德森癌症中心[MDACC]和莫菲特癌症中心[MCC])分层。Wilcoxon 秩和检验或 Kruskal-Wallis 检验用于比较连续变量,卡方检验或 Fisher 确切检验用于比较分类变量。

结果

分析了 55 例患者,其中 17 例(30.9%)接受了减瘤治疗。18 例(32.7%)患者 TT 为 III 级或更高。单独来看,术前变量与围手术期结局不一致。根据 IMDC 模型,风险较高的患者术后并发症较多(Clavien-Dindo 分级≥3,P=0.008)。对于 MSKCC 模型,风险较高的患者术中估计失血量(EBL)增加,住院时间(LOS)延长,术后并发症较多,更有可能出院到康复设施(P<0.05)。根据 MDACC 模型,风险较高的患者 LOS 较长(P=0.038)。根据 MCC 模型,风险较高的患者 EBL、LOS、术后并发症较多,30 天内再次入院(P<0.05)。

结论

总体而言,减瘤风险模型在接受肾切除术和肿瘤栓切除术的患者中与围手术期结局呈异质性相关。在可用模型中,与 IMDC、MSKCC 和 MDACC 模型相比,MCC 模型与更多的围手术期结局相关,包括 EBL、LOS、术后主要并发症和 30 天内再次入院。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验